

# INDIANA BIOSCIENCES RESEARCH INSTITUTE COLLABORATION

## Access to Lilly's Human Fab Phage Display Library Significantly Enhances the IBRI's Discovery of Therapeutic Antibodies

The interest in antibodies, both as tools for generating new knowledge or as medical interventions to address health concerns, continues to grow. The Phage Display System is a well-established technology to fulfill this growing interest. This technology provides both molecular diversity and high throughput capacity allowing identification of antibodies specific almost to any target.

To accomplish its goal in the development of therapeutic antibodies, in June 2019, the IBRI entered into a licensing agreement with Eli Lilly and Company to gain access to its proprietary human Fab Phage Display Library platform. This platform is a combination of multiple libraries representing vast molecular diversity.

Access to Lilly's Phage Display platform is a significant enhancement to the IBRI's capabilities in the discovery and development of novel antibodies. In addition to its internal efforts, the IBRI will establish partnerships to utilize the library for developing new diagnostic tools and therapeutic interventions for a range of disease targets. Through the licensing of its library, Lilly is hopeful that the IBRI and its partners can make meaningful therapeutic advancements that lead to improved health for patients.

### About the Pharmaceutical Biotechnology Center (PBC)

The IBRI Pharmaceutical Biotechnology Center (PBC) addresses human and animal health concerns through the development of bio-therapeutics (monoclonal antibodies, peptides, and proteins) and vaccines, with emphasis on cardiometabolic diseases, diabetes and nutritional health. For more information, please contact Vidadi Yusibov, Ph.D., Director, IBRI Pharmaceutical Biotechnology Center – [vyusibov@indianabiosciences.org](mailto:vyusibov@indianabiosciences.org) – 317-324-3324

### About the Indiana Biosciences Research Institute (IBRI)

The Indiana Biosciences Research Institute (IBRI) is an independent, nonprofit discovery science and applied research institute currently targeting diabetes, metabolic disease, poor nutrition and related health data science. Inspired by Indiana's leading life sciences companies, research universities and philanthropic community, the IBRI is building a world-class organization of researchers, innovators and entrepreneurs to catalyze scientific discovery and its application, resulting in improved health outcomes for Indiana patients and beyond. More at: <http://www.indianabiosciences.org>

DISCOVERY WITH PURPOSE